Table 1.
Compound | Structure | Percent conversiona at 100 µM | Kma (µM) | Vmaxa (µmol/min/mg protein) | kcat/Kma |
---|---|---|---|---|---|
β-Glycosides | |||||
3 Galactosylceramideb | 100%c | 60.318 | 0.073818 | 12318 | |
8 Psychosine | n.d. | 10318 | 0.10518 | 10218 | |
9 Glucosylceramideb | 19% | n.d. | n.d. | n.d. | |
10 β-KRN7000 | 42% | 550 | 0.113 | 20.5 | |
α-Glycosides | |||||
11 | 40% | 907 | 0.1080 | 11.9 | |
12 | 30% | 358 | 0.0449 | 12.5 | |
13 | 22% | 392 | 0.0584 | 15.0 | |
14 | 32% | 493 | 0.0590 | 12.0 | |
15 | 20% | n.d. | n.d. | n.d. | |
16 | 9% | n.d. | n.d. | n.d. | |
17 | 25% | 521 | 0.0519 | 10.0 | |
18 KRN7000 | 51% | 438 | 0.0758 | 17.3 | |
19 | 32% | 751 | 0.0834 | 11.1 | |
20 | 15% | n.d. | n.d. | n.d. | |
21 | 16% | n.d. | n.d. | n.d. | |
22 | 19% | n.d. | n.d. | n.d. |
aStandard errors were typically below 30% of the reported mean values.
bR: saturated or unsaturated alkyl or hydroxyalkyl residue (C16–C27).
cConversion of physiological substrate was set at 100%.
Km and Vmax values are shown in bold.